Viral hepatitis kills 410,000 people each year in WHO South-East Asia Region comprising 11 countries - India, Bangladesh, Bhutan, North Korea, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand and Timor-Leste, according to the figures by the global health body.
"If this ailment is detected in time and care can be taken, there are medications that can halt this virus," Bachchan said while addressing the 70th Regional Committee session via Skype.
"A very high burden of hepatitis exists in the South-East Asia Region. Whatever work we can do to eliminate hepatitis - to detect and cure it - we must do," said Bachchan.
"This is a moral and social issue. Discrimination against people with hepatitis continues to happen socially in our midst.
"There are women who are refused marriage, women who are refused the ability to bear children because they have hepatitis B and there are countries who deny visa to people with hepatitis. Discrimination needs to stop. People must know that there is a cure for hepatitis," he said.
"Each year viral hepatitis infects millions of people across the region, killing 410,000 people - more than HIV and malaria combined," said Poonam Khetrapal Singh, Regional Director South-East Asia.
"It is also a major cause of liver cancer and cirrhosis, contributing to premature morbidity and mortality, and undermining economic growth and the push to achieve health and wellbeing for all," said Singh, stressing on the need for countries to prioritise action to reverse this trend.
"We need to take urgent action against hepatitis," Bachchan said in his address.
At the Regional Committee session yesterday, member countries adopted the regional action plan to end viral hepatitis as a public health threat by 2030.
Using the framework of universal health coverage to ensure that no one is left behind, WHO has developed the plan in consultation with member countries, community leaders, development partners, academia and professional societies.
The regional action plan provides a framework for implementing evidence based interventions.
Other measures have also been emphasised such as safe blood and injection practices, improved sanitation, safe water and food safety; and scaling up testing and treatment of hepatitis B and C to prevent complications such as liver cirrhosis and cancer.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
